Data from the phase 3 study confirmed the lot consistency, immunogenicity, safety, and tolerability of a toxoid-based Clostridioides difficile vaccine. Neutralizing antibody responses 1 month after ...
A new therapeutic method using human antibodies to neutralize toxins was found to prevent Clostridium difficile-induced death in hamsters say researchers from New Jersey and Massachusetts. C.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the two pivotal Phase 3 clinical studies for bezlotoxumab, its ...
BOSTON – Estimated to cause almost half a million infections per year, the bacterium Clostridioides difficile, also known as C. difficile or “C. diff,” can cause diarrhea and inflammation of the large ...
Clostridium difficile infection is one of the most common healthcare-associated infections in adults in the United States. Older Americans are especially vulnerable to CDI, 2 and this infection has ...
Isolating asymptomatic C. diff carriers linked with lower incidence of infection Screening and isolating asymptomatic Clostridium difficile carriers was associated with a reduction in incidence of ...
Researchers at Vanderbilt University Medical Center have obtained the crystal structure of a toxin from the bacterium Clostridium difficile ("C. diff") -- the leading cause of hospital-acquired ...
In a hamster model of Clostridium difficile, infection with C. difficile strains producing either toxin A or toxin B caused fulminant disease, according to a research team from the University of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback